![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 29, 21862-21869, July 21, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Secretory Pathway Laboratory, Imperial Cancer Research
Fund, 44 Lincoln's Inn Fields,
London, WC2A 3PX, United Kingdom
Received for publication, November 1, 1999, and in revised form, April 28, 2000
ADP-ribosylation factor 1 (ARF1) mediates
clathrin coat formation on PC12 immature secretory granules (ISGs). We
have used two approaches to investigate whether ARF1 interacts directly with the clathrin adaptor protein, AP-1. Using an in vitro
recruitment assay and co-immunoprecipitation, we could isolate an
AP-1·ARF1 complex. Then we used a site-directed photocross-linking
approach to determine the components that act downstream of ARF1 in
clathrin coat formation on ISGs. Myristoylated ARF1, with a photolabile phenylalanine analogue incorporated into its putative effector domain
(switch 1), showed a specific, GTP-dependent interaction with both the The assembly of clathrin coats on the cytoplasmic face of
intracellular membranes occurs at specific sites. Ultimately, the site
of coat assembly becomes a transport vesicle as the membrane is
deformed by the rearrangement of the clathrin triskelion, driven by
interaction with other coat constituents (for recent review see Refs. 1
and 2). The mechanism underlying assembly of the clathrin coat at
specific sites involves a complex set of protein-protein and
protein-lipid interactions that is not fully understood. At all
intracellular sites where clathrin assembles, the minimum machinery is
the adaptor proteins (APs)1
and clathrin. Four types of adaptors, AP-1 through AP-4 (1, 3, 4) have
been identified to date. All adaptors are heterotetrameric complexes of
two large subunits with a molecular mass of ~100 kDa, a medium
subunit (~50 kDa) and small subunit (~20 kDa). The first identified
and most studied adaptors are AP-1 and AP-2. AP-1 consists of the large
subunits ARF1 recruits AP-1 to both ISG membranes (6) and the
trans-Golgi network (10, 11). ARFs are a family of small
molecular mass (~20 kDa) GTP-binding proteins that associate with
lipid bilayers and membranes via a myristoylated, hydrophobic amino terminus (12, 13). ARF in the GDP-bound form is cytosolic. Interaction
of ARF with its exchange factor allows GDP to be exchanged for GTP, and
this causes a major structural change in the switch 1 domain of ARF1
(14), thus exposing the myristic acid and promoting interaction of ARF
with the membrane.
ARF1 has been identified as a component of Golgi-derived nonclathrin
coated (COP-coated) vesicles (15) and is required for the formation of
COPI vesicles (16). However, unlike COP-coated vesicles, ARF is not
present in clathrin-coated vesicles in sufficient quantities to be a
stoichiometric component of the coat, although it has been shown to
recruit AP-1 in a stoichiometric manner (17). Furthermore, ARF1 in the
presence of GTP A second approach using site-specific cross-linking was employed to
start to understand the nature of the ARF1 interaction with AP-1 on ISG
membranes. Recent work using this approach has demonstrated that the
switch 1 domain of ARF1 interacts directly with COPI (18). ARF1, with
amino acid Ile-46 replaced with the photoactivatable analogue of
phenylalanine ((Tmd)Phe) (19), cross-linked to both ISG Preparation--
ISGs and MSGs were prepared from PC12 cells
by velocity and equilibrium sucrose gradient centrifugation, as
described previously (6). Each gradient generated 3 ml of ISGs and 2 ml
of MSGs, AP-1 Purification--
Bovine adrenal AP-1 was purified
essentially as described (21, 22) with some modifications: the
precipitated coat proteins that had been stripped from the isolated
clathrin coated vesicles using 1 M Tris-HCl, pH 7.2, were
purified using a Sepharose CL-4B (Amersham Pharmacia Biotech) column
(5 × 68 cm). The adaptor-rich fractions were pooled, adjusted to
a final concentration of 2 mM
Na2HPO4/NaH2PO4, pH
7.2, loaded on to an Econo-Pac® CHT-II cartridge (Bio-Rad), and eluted
with a 90-ml gradient of 2-350 mM
Na2HPO4/NaH2PO4, pH
7.2, containing 2 mM Tris-HCl, pH 7.2, 2 mM
2-mercaptoethanol, and 0.2% sodium azide at a flow rate of 0.5 ml/min.
The AP-1 containing fractions were dialyzed into 25 mM
Hepes, 25 mM KCl, 2.5 mM MgOAc, pH 7.2 (binding
buffer). The AP-1 isolated was ~80% pure as determined by SDS-PAGE
and Coomassie Blue staining (23).
Purification of Recombinant Myristoylated ARF1--
BL21(DE3)
cells expressing human ARF1 (pET-11d vector) (24) and yeast
N-myristoyltransferase (pBB131) (25) were obtained from
Dennis Shields (Albert Einstein College of Medicine, New York, NY).
Myristoylated ARF1 (myrARF1) was prepared as described by Franco
et al. (26), except that a 50% ammonium sulfate
precipitation was performed on the lysed cell supernatant (27) after
dilution of the protein concentration to 10 mg/ml. Sequential
chromatography by DEAE-Sepharose, HiTrap® SP and Superdex 75 columns
(Amersham Pharmacia Biotech) were performed to obtain myrARF1 that was
>95% pure and >95% myristoylated, as determined by Coomassie
Blue-stained 15% SDS-PAGE gels.
PC12 ISG In Vitro Transcription and Translation--
The human ARF1
cDNA (pET-11d vector) was in vitro transcribed with T7
RNA polymerase (Promega) and translated using the rabbit reticulocyte
lysate based Flexi-lysate kit (Promega) in the presence of
[35S]methionine (Amersham Pharmacia Biotech) according to
the manufacturer's protocol. ARF1 was labeled during the in
vitro translation reaction with 1 µCi/µl
[3H]myristic acid (Amersham Pharmacia Biotech) instead of
[35S]methionine as described (28).
PC12 ISG Binding Assay Using [35S]ARF and
Subsequent Immunoprecipitation--
25 µl of ISGs were incubated
with 5 µl of in vitro translated [35S]ARF
with 100 µM GTP Synthesis of Site-specific Photolabile ARF Mutants--
The
cDNA encoding human ARF1, inserted into the pET-11d plasmid, with
amino acid Ile-46 replaced by the amber stop codon (TAG), was obtained
from Felix Wieland (Biochemie-Zentrum Heidelberg, Heidelberg, Germany)
(20). For details refer to Refs. 18-20. In vitro
translation was performed in the presence of
[35S]methionine and 5 µM ligated suppressor
(Tmd)Phe tRNA at 30 °C for 2 h. The resulting
[35S]ARF-(Tmd)Phe-46 was analyzed by 12% SDS-PAGE and autoradiography.
Photocross-linking Assays--
In a total volume of 250 µl,
ISGs or MSGs were incubated in binding buffer with 25 µl of in
vitro translated [35S]ARF-(Tmd)Phe-46 with 100 µM nucleotide (either GDP Antibodies and Immunoprecipitation--
Antibodies used include:
rabbit polyclonal antiserum anti- Removal of AP-1 and COPI from Lysate--
We used a method
previously shown to deplete 80% of COPI from rat liver cytosol (30).
110 µl of the translation mix containing in vitro
translated [35S]ARF-(Tmd)Phe-46 was placed over a
40-µl 0.5 M sucrose cushion (in binding buffer) and
centrifuged at 300,000 × g using a TLA-100 rotor
(Beckman) for 2 h at 4 °C.
Preparation of Liposomes--
Liposomes were prepared using
soyabean mixed lipids (Azolectin), containing 20%
L- Purified Myristoylated ARF1 Regulates AP-1 Binding to the
ISGs--
It has previously been shown, using a cell-free assay system
and partially purified components, that ARF1 is required for In Vitro Translated [35S]myrARF1 Interacts with
AP-1 on the ISGs in a GTP-dependent Manner--
To monitor
ARF1 binding to the ISGs, we wanted to generate
[35S]myrARF1 by in vitro translation using
rabbit reticulocyte lysate. To demonstrate that the ARF1 was
myristoylated during the translation reaction, ARF1 mRNA was
in vitro translated in the presence of [3H]myristic acid. This resulted in a
3H-labeled ~20-kDa band whose migration was identical to
purified recombinant myrARF1 (Fig.
2A, lane 1). Others
have also observed N-myristoyltransferase activity (28, 32,
33) in the rabbit reticulocyte lysate. In vitro
translation of ARF1 mRNA in the presence of
[35S]methionine resulted in a broader ~20-kDa band
(Fig. 2A, lane 2) that, after a lower exposure
time, is visible as a doublet (not shown) corresponding to
myristoylated and nonmyristoylated [35S]ARF1. These
results confirm that ARF1 is myristoylated during the in
vitro translation reaction.
To determine whether AP-1 and ARF1 form a complex, ISG binding
assays were performed in the presence of [35S]ARF1. After
incubation of [35S]ARF1 with the ISGs in the presence of
GTP Membrane-bound [35S]ARF-(Tmd)Phe-46 Cross-links to
100-120-kDa Coat Proteins--
To investigate whether ARF1 interacts
directly with AP-1, we decided to use site-directed photocross-linking,
as used previously by others to demonstrate a direct interaction of the
nonclathrin coat, COPI and ARF1 (18). Full-length photoactivatable
[35S]ARF-(Tmd)Phe-46 was generated by mutating the codon
for Ile-46, in the human ARF1 cDNA, to amber, followed by in
vitro translation (of the corresponding mRNA) in the presence
of a suppressor tRNA ligated to the photolabile group, (Tmd)Phe, which
recognizes this stop codon (18). [35S]ARF-(Tmd)Phe-46 was
then incubated with ISGs with or without AP-1 in the presence of
GTP
Immunoprecipitation of the specific cross-linked products confirmed an
interaction of myrARF1 with AP-1. Immunoprecipitation of the whole AP-1
complex with the Membrane-bound [35S]ARF-(Tmd)Phe-46 Can Directly
Interact with
Immunoprecipitation with STO-25 under native and denaturing conditions
(Fig. 3B, lane 3 and 4) implied that both
To make the cross-linking assay dependent on exogenous AP-1, we removed
the high molecular mass coat proteins in the rabbit reticulocyte
lysate, after in vitro translation of
[35S]ARF1-(Tmd)Phe-46, by high speed centrifugation. Most
of the AP-1 and COPI remained in the cushion and was absent from the supernatant (Fig. 5A, top and
middle panels, respectively), whereas most of the
[35S]ARF1-(Tmd)Phe-46 remained in the supernatant (Fig.
5A, bottom panel). Greater than 90% of AP-1 and COPI were
removed. Some [35S]ARF1-(Tmd)Phe-46 was lost in the
sucrose cushion (Fig. 5A, bottom panel,
lane 2), and as a result, for the cross-linking assay, the
amount of [35S]ARF1-(Tmd)Phe-46 was normalized to that in
the crude translation mix. The [35S]ARF1-(Tmd)Phe-46 in
the depleted lysate bound to the ISGs in a
GTP myrARF1 and AP-1 Do Not Interact on MSGs--
We next investigated
the ability of [35S]ARF1-(Tmd)Phe-46 to bind and interact
with AP-1 on PC12 MSGs because we know that MSGs have no clathrin coat
(6). No GTP-dependent binding of
[35S]ARF1-(Tmd)Phe-46 was observed when using MSGs in the
binding assay compared with ISGs (Fig. 6,
lower panel), even using the crude in vitro
translation mix containing the rabbit coat proteins. As a result, no
cross-linking of [35S]ARF1-(Tmd)Phe-46 to AP-1 or
COPI was observed on MSGs compared with ISGs (Fig. 6, upper
panel, compare lanes 2 and 5). In addition, we did not observe [35S]ARF1-(Tmd)Phe-46 binding or
cross-linking to AP-1 on liposomes using the crude in vitro
translation mix or even after the addition of ARF-depleted bovine brain
cytosol (18) prior to photocross-linking (results not shown). This is
in contrast to previous results showing recruitment of AP-1 and
clathrin onto liposomes (from soyabean lipids) using ARF-GTP and
cytosolic factor(s) (35). Hence, the recruitment of myrARF1 and the
AP-1/myrARF1 interaction is specific to ISGs, confirming our previous
data that there are molecules on the ISGs that allow coat formation
that are removed or inactivated during secretory granule
maturation.
myrARF1 is required for the recruitment of AP-1 to ISGs (6) and
ultimately for clathrin-coated vesicle formation during ISG maturation.
Previous work showed that ARF1 is a limiting factor in the
GTP-stimulated recruitment of AP-1 onto isolated Golgi membranes, and
although ARF1 is not a stoichiometric component of the clathrin coat,
it appears to function in a stoichiometric manner to generate high
affinity binding sites for AP-1 (17). We have extended these findings
by demonstrating a direct interaction between AP-1 and myrARF1 in the
GTP-bound form. We show that AP-1 and ARF1 form a complex using
co-immunoprecipitation of [35S]myrARF1 with The photocross-linking method is qualitative and does not allow a
quantification of the stoichiometry between ARF and AP-1. Cross-link
yields are typically <1%, because the reactive carbene predominantly
interacts with the water molecules (19). The photoprobe is highly
specific, because a protein of very close proximity would be required
to compete with the abundant water molecules. Because the rabbit
reticulocyte lysate used for the in vitro translation also
contains ~1 µg/ml of unlabeled ARF proteins, as determined with the
pan-ARF antibody, the specific activity of the
[35S]ARF-(Tmd)Phe-46 is further reduced. We are unable to
detect by immunoblotting, with antibodies to AP-1 or COPI, the
population of coat proteins that were photo cross-linked to myrARF1.
Thus, we are unable to quantify the extent of the interaction between myrARF1 and AP-1 or COPI using the photocross-link approach.
Using the reticulocyte lysate, in the presence of GTP Interaction of both AP-1 and COPI with the switch 1 domain of ARF1
suggests that common structural features exist between these
multisubunit coat protein complexes. A phylogenetic analysis by
Schledzewski et al. (41) provides evidence that the clathrin adaptors and F-COP (a subcomplex of COPI containing the subunits How can the switch 1 domain of ARF1 interact with two subunits of AP-1
or COPI? There is increasing evidence to suggest that ARF oligomerizes;
crystals of ARF-GDP were found in a dimeric form (42, 43), and
cross-linking of ARF with itself has been detected using
[35S]ARF-(Tmd)Phe-49 (20). Furthermore, others have
determined that there are multiple copies of membrane associated
ARF-GTP per coatomer (15, 45, 46). Thus, it is possible that dimers of
myrARF1 exist, where the switch I region of one molecule of ARF
interacts with the ISG maturation involves homotypic fusion and changes in the size and
dense core (47) of the secretory granule. Unlike MSGs, which lack a
clathrin coat, ISGs are partially coated vesicles (48, 49), with AP-1
containing clathrin coats (50). Clathrin coats have been seen
enveloping small vesicular structures on ISGs (49), leading to the
hypothesis that clathrin-coated vesicles serve to remove components of
the secretory granule. We show that myrARF1 does not bind to MSGs and,
using photocross-link, that AP-1 and myrARF1 do not interact on the
MSG, suggesting that there are proteins on the ISG, required for
myrARF1 binding and subsequent AP-1/ARF1 interaction, which cannot be
supplied by the reticulocyte lysate or bovine brain cytosol. These
proteins may be transmembrane proteins such as mannose-6-phosphate
receptor or furin, both of which are present on ISGs but absent from
MSGs (37, 39). In support of this others have shown that
mannose-6-phosphate receptors can stabilize AP-1 and ARF1 interaction
on trans-Golgi network membranes (44), and a bivalent
interaction of coatomer with membrane-bound ARF and cytoplasmic tails
of cargo or putative cargo receptors has been demonstrated (45).
We thank Drs. A. Paulion, E. Smythe, and
M. S. Robinson for advice on the AP-1 purification, D. Shields for
the bacteria expressing the human ARF1 and yeast
N-myristoyltransferase, R. Kahn for the mAb 1D9, T. Kirchhausen for the *
This work was supported by European Union Training and
Mobility of Researchers Grant FMRX-CT96-0023.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Published, JBC Papers in Press, May 11, 2000, DOI 10.1074/jbc.M908875199
2
C. Austin, unpublished observations.
The abbreviations used are:
AP, adaptor protein;
ARF, ADP-ribosylation factor;
ISG, immature secretory granule;
MSG, mature secretory granule;
COP, coat protein;
COPI, COP complex type I;
GTP
Direct and GTP-dependent Interaction of
ADP-ribosylation Factor 1 with Clathrin Adaptor Protein AP-1 on
Immature Secretory Granules*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
- and 
adaptin subunits of AP-1 on ISGs. These experiments provide evidence for a direct interaction of ARF1 with
AP-1. On mature secretory granules myristoylated ARF1 does not bind,
and hence clathrin coat formation cannot be initiated, supporting the
hypothesis that molecules involved in coat recruitment are removed
during ISG maturation.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
and
1, medium chain µ1, and small chain
1 and is
found primarily on the Golgi complex (5) and immature secretory
granules (6), whereas AP-2, which consists of the
,
2, µ2, and
2 subunits, is localized mainly to the plasma membrane and endosomes
(7). The localization of AP-1 and AP-2 to different compartments can,
in part, be attributed to their ability to bind to different sequences
in the cytoplasmic domains of trans-membrane receptors (for recent
reviews see Refs. 8 and 9).
S generates high affinity binding sites for AP-1 that
are stable even in the presence of high concentrations of Tris (17). To
investigate whether ARF1 interacts with AP-1, we used an in
vitro recruitment assay with [35S]myrARF1, followed
by co-immunoprecipitation with antibodies directed against AP-1 and
discovered an AP-1·ARF1 complex on ISG membranes.
- and
-COP
(20). Using the ARF1-(Tmd)Phe-46 mutant, we performed cross-linking
experiments with ISGs as the acceptor compartment for ARF and AP-1. We
have found that on ISG membranes ARF1 can be cross-linked to AP-1 in a
GTP-dependent manner via the
- and
1-adaptin subunits
of AP-1, and this interaction is strictly dependent on the presence of
ISG membranes. Mature secretory granules (MSGs) or liposomes do not
facilitate a direct interaction between ARF and AP-1. Our data show
that the switch 1 domain of ARF1, encompassing Ile-46, interacts with
AP-1 as well as COPI.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
of which was used per reaction.
-Adaptin Binding Assay--
The binding assay was
performed as described elsewhere (6). Briefly, 125 µl of ISGs were
incubated in binding buffer with purified AP-1 and recombinant myrARF1
in the presence or absence of 100 µM GTP
S in a total
volume of 250 µl. After incubation at 37 °C for 30 min the samples
were diluted 4-fold in binding buffer, centrifuged (100, 000 g for 1 h), and analyzed by immunoblotting with
subsequent incubations of the monoclonal antibody (mAb)
anti-
-adaptin, 100/3 (Sigma), rabbit anti-mouse antiserum, and
125I-protein A (Amersham Pharmacia Biotech) as described
(6). The radioactivity bound to the ISGs was quantified using a
PhosphorImager system (Molecular Dynamics). All assays were done at
least in duplicate.
S or GDP
S in a total of 50 µl at
37 °C for 30 min. The ISGs were sedimented, solubilized, and
immunoprecipitated under native conditions (see below) with either
preimmune serum or the
-adaptin antiserum, STO-25 (6). Samples were
analyzed by SDS-PAGE, quantified using a PhosphorImager system, and
then subjected to autoradiography.
S or GTP
S) in the presence
or absence of purified AP-1 or recombinant myrARF1 as described in the
figure legends, at 37 °C for 30 min, followed 4-fold dilution in
binding buffer, and pelleted (100,000 g for 1 h) over a
400-µl cushion of 0.5 M sucrose in binding buffer. The
pellet was resuspended in 20 µl of binding buffer containing 0.15 M sucrose. For the samples without membranes, a volume of 25 µl was used; these were not centrifuged but irradiated directly. Samples were irradiated as described (18) and then either
trichloroacetic acid precipitated and analyzed by SDS-PAGE and
autoradiography or immunoprecipitated.
-AP, STO-25 (6); rabbit polyclonal
antisera against
-COP and
-COP (a gift from F. T. Wieland);
mAb anti-
-AP, 100/3 (Sigma); mAb anti-
-AP (a gift from T. Kirchhausen, Harvard Medical School, Cambridge, MA) (29); mAb
anti-
-AP, 100/2 (Sigma); and mAb anti-ARF (a gift of R. Kahn). For
immunoprecipitation under native conditions, cross-linked ISG pellets
were solubilized in 250 µl of 20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 0.15 M NaCl, 0.5% (w/v) Triton X-100
(TNTE buffer). For denaturing conditions, the samples were boiled for 3 min in the presence of 1% SDS and then diluted as for the native conditions except that the Triton X-100 concentration was increased to
0.9%. Rabbit anti-mouse antiserum was added to all incubations containing mAbs. The immune complexes were bound by protein A-Sepharose CL-4B (Amersham Pharmacia Biotech). After washing in TNTE buffer and
once with 20 mM Tris-HCl, pH 7.5, samples were solubilized in sample buffer and analyzed by Western blotting and autoradiography.
-phosphatidylcholine (Sigma P5638), according to the
reverse-phase evaporation method (31). The resulting liposomes were
filtered through a 0.8-µm Millex®-PF filter (Millipore). 72.5 mg of
liposomes were used per sample.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-adaptin binding to PC12 ISGs (6). We have reproduced the ARF1-dependent AP-1 recruitment to ISGs using purified
components (Fig. 1). Quantification
relies on the use of the mAb 100/3 that recognizes bovine but not rat
-adaptin; hence only the bound exogenous bovine
-adaptin is
detected. Both purified bovine AP-1 and purified recombinant myrARF1
were titrated into the binding assay (Fig. 1A). We used
bovine AP-1 because we could obtain large amounts of tissue for the
purification. Our previous experiments have shown that bovine AP-1
binds to ISGs as efficiently as rat AP-1 (6). Human, bovine, and mouse
ARF1 are 99% identical; thus it was assumed that the human ARF1 would
bind as efficiently to rat ISGs as the endogenous rat ARF1. Increasing
the myrARF1 concentration up to 20 µg/ml resulted in an increase in
the
-adaptin bound to the ISGs at all concentrations of AP-1 used
except 1 µg/ml. At 1 µg/ml AP-1, the
-adaptin binding was
saturated at 4 µg/ml myrARF1, this may be due to limiting amounts of
AP-1. In the absence of added ARF1 there is a basal level of
-adaptin binding (Fig. 1B); this is likely to be due to
endogenous ARF1 already bound to the ISGs and is similar to the level
observed in the presence of ARF1 but in the absence of any nucleotide. The addition of GTP
S increases
-adaptin binding to ISGs 3-4-fold but only in the presence of ARF1 (Fig. 1B). We did not
observe GTP-dependent binding of nonmyristoylated ARF1 to
the membranes (results not shown). Hence, the only cytosolic component
required for purified AP-1 to bind to the ISGs is GTP-bound
myrARF1.

View larger version (18K):
[in a new window]
Fig. 1.
Recombinant human myrARF1 recruits
purified AP-1 to ISGs in a
GTP
S-dependent manner.
A, PC12 ISGs were incubated with 1 µg/ml (closed
circles), 2 µg/ml (open circles), or 4 µg/ml
(closed squares) of purified bovine adrenal AP-1 and
increasing amounts of recombinant myrARF1 (2-20 µg/ml) at 37 °C
for 30 min in the presence of GTP
S. The amount of
-adaptin bound
to the ISGs was determined after sedimentation and immunoblotting with
the bovine specific mAb antibody, 100/3. The membrane-bound
-adaptin
was quantified using a PhosphorImager, and results are expressed as a
percentage of the signal observed with 2 µg/ml AP-1 and 20 µg/ml
myrARF1. B, binding assay, similar to that in
panel A, using 2 µg/ml AP-1 in the presence (+) or absence
(
) of 20 µg/ml myrARF-1, in the presence (shaded bars)
or absence (open bars) of GTP
S. The results are expressed
as percentages of the signal observed with 2 µg/ml AP-1 and 20 µg/ml myrARF1 in the presence of GTP
S. All assays are done in
duplicate. Similar results were obtained in at least four independent
experiments.

View larger version (28K):
[in a new window]
Fig. 2.
AP-1 forms a complex with myristoylated
[35S]ARF on ISGs. A, in vitro
translated ARF1, labeled with either [3H]myristic acid
(lane 1) or [35S]methionine (lane
2) was subjected to 15% SDS-PAGE and fluorography.
Arrows indicate the positions of the myristoylated and
nonmyristoylated ARF1 as defined by Coomassie Blue staining of the
corresponding purified recombinant proteins (not shown). No labeling
was observed in this region in the absence of mRNA. B,
in vitro translated [35S]ARF1 was incubated
with ISG membranes, in the presence of either GTP
S (lanes
1 and 3) or GDP
S (lane 2 and
4). After incubation at 37 °C for 30 min, the membranes
were pelleted, solubilized, and then immunoprecipitated under native
conditions with either the anti-
-AP antiserum, STO-25 (
-AP,
lanes 1 and 2) or preimmune serum (PI,
lanes 3 and 4). Samples were analyzed by 12%
SDS-PAGE, quantified using a PhosphorImager, and subjected to
fluorography. B shows a representative fluorograph showing
~20 kDa [35S]myrARF1 as indicated by an
arrow. C, three experiments similar to that in
B were performed and quantified using a PhosphorImager.
Values represent the percentages of [35S]myrARF
immunoprecipitated compared with the amount immunoprecipitated with
STO-25 in the presence of GTP
S (hatched bars) or GDP
S
(open bars). Error bars represent the standard
error of the mean.
S or GDP
S, immunoprecipitation of
-AP was performed with
polyclonal, STO-25 to determine whether the [35S]myrARF1
was interacting with AP-1 (Fig. 2, B and C). The
myristoylated form of [35S]ARF1 was specifically
co-immunoprecipitated with AP-1 in the presence of GTP
S (Fig.
2B). The amount of [35S]myrARF1
co-immunoprecipitated in the presence of GTP
S was twice that in the
presence of GDP
S and 4-fold more than preimmune controls. Approximately 1% of the total membrane bound
[35S]myrARF1 added to the assay could be
co-immunoprecipitated with anti-
AP antibodies. These results
demonstrate that AP-1 and myrARF1 do form a complex on the ISG membrane.
S. The GTP
S-dependent binding of [35S]ARF-(Tmd)Phe-46 to the ISG membranes (Fig.
3A, lower panel, compare lane 1 versus lane 3 and lane
5 versus lane 7) excludes the possibility
that replacement of Ile-46 with the (Tmd)Phe severely alters the
GTP-dependent ARF binding to ISGs. The migration of the
[35S]ARF-(Tmd)Phe-46 bound to the ISG membranes is
identical to the migration of myrARF1. Irradiation resulted in at least
three cross-linked products with estimated molecular masses of 120-140
kDa (region marked X, Fig. 3A, upper panel,
lanes 3 and 7). Addition of AP-1 appeared to
increase the intensity of the 120-kDa bands (Fig. 3A,
lane 7). This was consistent with cross-linking of ARF
(~20 kDa) to one or both of the large subunits of AP-1 (~100 kDa). The photocross-linked products are specific because they were not
observed in the presence of GDP
S (Fig. 3A, upper panel,
lanes 1 and 5), or in the absence of irradiation
(Fig. 3A, upper panel, lanes 2 and 6).
Displacement of the membrane-bound [35S]ARF-(Tmd)Phe-46
using excess unlabeled recombinant wild type myrARF1 (Fig. 3A,
lower panel, lanes 4 and 8) abolished the
photocross-linking (Fig. 3A, upper panel, lanes 4 and 8). Importantly, the cross-linked products were not
observed in the absence of ISG membranes either in the presence or
absence of added AP-1 (Fig. 3A, upper panel, lanes 9 and 10), demonstrating that only
membrane-bound myrARF1 interacts with the 100-120-kDa proteins and
that ARF1·AP-1 does not interact in solution.

View larger version (62K):
[in a new window]
Fig. 3.
Photocross-linking of membrane-bound
[35S]ARF-(Tmd)Phe-46. A,
in vitro translated [35S]ARF-(Tmd)- Phe-46
was incubated in the absence (lanes 9 and 10) or
presence (lanes 1-8) of ISG membranes, with GDP
S
(lanes 1 and 5) or GTP
S (lanes 2-4
and 6-10), in the absence (lanes 1-4 and
9) or presence (lanes 5-8 and 10) of 4 µg/ml
purified AP-1 or with 40 µg/ml recombinant myrARF1 (lanes
4 and 8). After incubation at 37 °C for 30 min, the
membranes were sedimented and irradiated (except samples lanes 2 and 6) and trichloroacetic acid precipitated. Then
were analyzed by 7.5% SDS-PAGE and autoradiography (upper
panel) to visualize the cross-linked products, and
was
analyzed by 15% SDS-PAGE and autoradiography (lower panel)
to visualize the uncross-linked [35S]ARF-(Tmd)Phe-46
bound to ISG membranes. In the upper panel, the region of
the ISG specific photocross-linked products is labeled (X).
Upper and lower panels are representative of at
least three independent experiments and were exposed for 1 week and 1 day, respectively. B, photocross-linked products of
[35S]ARF-(Tmd)Phe-46 (samples identical to that
in panel A, lane 3) were immunoprecipited with preimmune
serum (PI, lane 2) or polyclonal antisera, to
-adaptin (
-AP, lane 3 and 4),
-COP
(lane 5), or
-COP (lane 6) under native
(n) or denaturing (d) conditions. Lane
1 represents the total photocross-linked products before
immunoprecipitation. Samples were analyzed by 7.5% SDS-PAGE and
subsequent autoradiography for 2 weeks. Results are representative of
at least three independent experiments.
-AP polyclonal, STO-25 (6) under native conditions
resulted in a 35S-labeled doublet (Fig. 3B,
lane 3), whereas immunoprecipitation of the dissociated
subunits under denaturing conditions showed a single band of lower
intensity corresponding to
-AP (Fig. 3B, lanes
4). Because the pattern of cross-linked products derived from
[35S]ARF-(Tmd)Phe-46 bound to ISGs were similar to that
observed with Golgi membranes in the presence of coatomer (20),
antisera to
- and
-COP were used to characterize the other
cross-linked products observed with the ISG membranes. Similar to the
result obtained for Golgi membranes (20), anti-
-COP
immunoprecipitated a band of 120 kDa (Fig. 3B, lane
5), and the anti-
-COP immunoprecipitated two bands of
approximately 120 and 140 kDa (Fig. 3B, lane
6).
- and
1-AP--
To increase the efficiency of
cross-linking of [35S]ARF1-(Tmd)Phe-46 to AP-1 on the
ISGs, purified bovine AP-1 was titrated into the photocross-linking
binding assay (Fig. 4A,
lanes 1-3). The cross-linking pattern showed an increase in
the intensity of the labeled 120-kDa bands with increasing AP-1 (Fig.
4A, top panel, lanes 1-3). Immunoprecipitation
of the whole AP-1 complex with 100/3 confirmed an increase in the
efficiency of cross-linking of [35S]ARF1-(Tmd)Phe-46 to
AP-1 (Fig. 4A, middle panel, lanes
1-3). Increasing the [35S]ARF1-(Tmd)Phe-46 caused a
further increase in the intensity of the cross-linked products (Fig.
4A, top panel, lanes 6 and 7), which is due to increased cross-linking to AP-1 (Fig.
4A, middle panel, lanes 6 and
7). Because the mAb 100/3 only recognizes bovine and not rat
AP-1, it was surprising that, in the absence of exogenous bovine AP-1,
100/3 could immunoprecipitate a cross-linked product (Fig.
4A, middle panel, lane 1). This
suggested that there might be AP-1 in the rabbit reticulocyte lysate
used to generate the [35S]ARF1-(Tmd)Phe-46. Western blot
analysis demonstrated that indeed this was the case (data not shown).
Using purified bovine AP-1 as a standard and assuming equal
cross-reactivity of 100/3 with rabbit AP-1 it was estimated that the
rabbit reticulocyte lysate contains ~16 µg/ml AP-1, giving a final
concentration of ~1 µg/ml rabbit AP-1 in the binding assay. AP-2
and COPI were also detected in the lysate using polyclonal anti-
-COP
and anti-
-COP and may explain the source of
- and
-COP
cross-linked to ARF1 on the ISG membranes. Thus, the rabbit
reticulocyte lysate acts like a cytosol, providing the adaptor proteins
and coatomer for recruitment to ISGs. Increasing the amount of
[35S]ARF1-(Tmd)Phe-46 resulted in an increased binding
(Fig. 4A, bottom panel, lanes 4-7),
whereas increasing AP-1 had no effect on the amount of
[35S]ARF1-(Tmd)Phe-46 bound to the membrane (Fig.
4A, bottom panel, lanes 1-3). This
suggests that AP-1 does not influence
[35S]ARF1-(Tmd)Phe-46 binding to the membrane. These
results confirm a direct interaction of
[35S]ARF1-(Tmd)Phe-46 with both exogenous rabbit and
bovine AP-1 on ISG membranes.

View larger version (42K):
[in a new window]
Fig. 4.
Photocross-linking of membrane-bound
[35S]ARF-(Tmd)Phe-46 to the large subunits of AP-1.
A, in vitro translated
[35S]ARF-(Tmd)Phe-46 was either kept constant (see
"Experimental Procedures") and incubated in the presence of ISG
membranes with increasing amounts of purified bovine AP-1 (lanes
1-3), or the AP-1 concentration was kept constant (4 µg/ml) and
the in vitro translated [35S]ARF-(Tmd)Phe-46
(lanes 4-7) was varied. All samples contained GTP
S.
After sedimentation and irradiation, the products (upper
panel) were subjected to 7.5% SDS-PAGE and autoradiography, and
the region of the specific photocross-linked products is shown
(X). Alternatively, cross-linked samples were
immunoprecipitated with the mAb anti-
-AP (100/3) under native
conditions and then analyzed by 7.5% SDS-PAGE and autoradiography
(middle panel) for 1 month. Lower panel, the
uncross-linked membrane-bound [35S]ARF-(Tmd)Phe-46 was
visualized by analysis of
of the products of the
upper panel by 15% SDS-PAGE and autoradiography. The
upper and lower panels were exposed for 6 days.
Photocross-linking samples, identical to those in lane 1, underwent two rounds of immunoprecipitation (the second round was
performed on the remaining supernatant from the first round) with
B, polyclonal anti-
-AP antisera, STO-25, either under
native (n) or denaturing (d) conditions,
C, mAb anti-
-AP, 100/3 and mAb anti-
-AP. D,
mAb anti-
-AP and mAb anti-
-AP, 100/3 and as indicated. Second
round immunoprecipitations with the same antibody as the first round
were performed to indicate efficacy of the first round. In
B-D, all autoradiographs were obtained after a 3-day
exposure.
-
and
1-AP may interact with ARF. The photocross-linking assay in the
absence of added bovine AP-1 contains endogenous rat AP-1 from the PC12 ISGs and exogenous rabbit AP-1 from the rabbit reticulocyte lysate. Anti-
-AP antiserum, STO-25 recognizes rat and, to a lesser extent, rabbit
-AP, whereas anti-
-AP antibody 100/3 recognizes rabbit and
not rat
-AP. Quantative immunoprecipitation with STO-25 (Fig. 4B, lane 3) and 100/3 (Fig. 4C,
lanes 3 and 5) under denaturing conditions
demonstrate that both rat and rabbit
-AP directly bind to
[35S]ARF1-(Tmd)Phe-46. Immunoprecipitation of the whole
AP-1 complex with the same antisera under native conditions revealed
bands of greater intensity than that immunoprecipitated under
denaturing conditions, again suggesting cross-linking of
[35S]ARF1-(Tmd)Phe-46 to both
1- and
-AP. This was
confirmed by immunoprecipitation of the dissociated AP-1 subunits with
the anti-
-AP (Fig. 4, C, lane 6 and
D, lanes 3 and 5). Because the anti-
-AP antibody also recognizes both
1- and
2-AP, we cannot rule out from these immunoprecipitations that
2-AP also cross-links with myrARF1. However, [35S]ARF1-(Tmd)Phe-46 does not
interact with
-AP of AP-2 because no products were
immunoprecipitated with anti-
-AP under native or denaturing
conditions (data not shown); therefore, it is unlikely that
[35S]ARF1-(Tmd)Phe-46 interacts with
2-AP. Although
ARF1 has been shown to recruit AP-2 to endosomal membranes in a
GTP
S-dependent manner (34), we failed to detect a
GTP-dependent association of AP-2 to
ISGs,2 consistent with the
cross-linking data.
S-dependent manner (Fig. 5B, bottom
panel, compare lanes 4 and 5). However, the
amount bound was significantly lower than that observed for the crude
in vitro translation mix (Fig. 5B, bottom
panel, compare lanes 2 and 5) even though
the total amount of [35S]ARF1-(Tmd)Phe-46 added to the
reaction was the same. The myrARF1 bound to the ISGs was still able to
interact directly with exogenous bovine AP-1 as indicated by an
increase in the cross-linking products with increasing bovine AP-1
(Fig. 5B, top panel, lanes 6-8), and by immunoprecipitation of bovine AP-1 cross-linked to
[35S]ARF1-(Tmd)Phe-46 with mAb, 100/3 (Fig.
5B, middle panel, lanes 5-7). As
expected, in the absence of bovine AP-1, no cross-linked AP-1 was
immunoprecipitated with 100/3 (Fig. 5B, middle
panel, lane 5). However, cross-linking of
[35S]ARF1-(Tmd)Phe-46 to AP-1 was still detected in the
absence of exogenous bovine AP-1 (Fig. 5B, top
panel, lane 5). Because the PC12 ISGs used in the assay
have AP-1 containing clathrin coats (6), the cross-linked product in
Fig. 5B, top panel, lane 5, is derived
from [35S]ARF1-(Tmd)Phe-46 interacting with endogenous
PC12 AP-1.

View larger version (39K):
[in a new window]
Fig. 5.
Photocross-linking of membrane-bound
[35S]ARF-(Tmd)Phe-46 after removal of AP-1 from the
in vitro translation mix. A, the
in vitro translation mix containing
[35S]ARF-(Tmd)Phe-46 was centrifuged at 300,000 × g for 2 h over a 0.5 M sucrose cushion to
remove high molecular mass complexes. The resulting supernatant
(Supe.), cushion, and resuspended pellet were compared with
untreated translation mix (Total) for the presence of AP-1
and COPI by Western blotting using mAb anti-
-AP, 100/3 and mAb
anti-
-COP, M3A5, respectively, and chemiluminscence, and for
[35S]ARF-(Tmd)Phe-46 by 15% SDS-PAGE and autoradiography
for 8 h. B, in vitro translation mix, either
untreated (crude) or centrifuged (depleted),
containing equal amounts of [35S]ARF-(Tmd)Phe-46 were
used for the photocross-linking experiments as in Fig. 3A.
Experiments were performed in the presence of either GDP
S
(lanes 1 and 4) or GTP
S (lanes 2,
3, and 5-8), with or without AP-1 as indicated.
In the top panel, the region of the ISG specific
photocross-linked products is labeled (X). This panel was
obtained after a 1-week exposure. Middle panel, samples
identical to those in the top panel, lanes 5-7 were
immunoprecipitated with mAb anti-
-AP, 100/3 under native conditions.
Samples were subjected to 7.5% SDS-PAGE and autoradiography for 10 days. Bottom panel,
of the samples of the
upper panel were analyzed by 15% SDS-PAGE and
autoradiography overnight to visualize the uncross-linked,
membrane-bound [35S]ARF-(Tmd)Phe-46.

View larger version (42K):
[in a new window]
Fig. 6.
Photocross-linking of
[35S]ARF-(Tmd)Phe-46 is ISG-specific.
In vitro translated [35S]ARF-(Tmd)Phe-46 was
incubated in the absence of membranes (lane 1) or in the
presence of ISGs (lanes 2-4) or MSGs (lanes
5-7), with GDP
S (lanes 3 and 6) or
GTP
S (lanes 1, 2, 4, and
5). After incubation at 37 °C for 30 min, the membranes
were pelleted, irradiated (except lanes 4 and 7),
and trichloroacetic acid precipitated, and then
were
analyzed by 7.5% SDS-PAGE and autoradiography (upper
panel). The region of the ISG specific photocross-linked products
is labeled (X). Lower panel, the uncross-linked
membrane [35S]ARF-(Tmd)Phe-46 was observed by analysis of
of the samples from the upper panel by 15%
SDS-PAGE and autoradiography. Both the upper and lower
panels were obtained after a 1-week exposure. Similar results were
obtained in a duplicate experiment.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-adaptin
from solubilized ISG membranes. We could estimate that 1% of the
membrane bound myrARF1 is in a complex with AP-1. We exploited a
site-directed photocross-linking approach to demonstrate that myrARF1
in the GTP form interacts directly with both the
- and
1 subunits
of AP-1. The interaction of ARF1, via Ile-46, which is in the switch 1 domain, the putative effector region of ARF1 (14), with AP-1 is
consistent with data of Liang and Kornfeld (36); using chimeras of
mammalian and yeast ARF they showed residues 35-94 were essential for
AP-1 recruitment to the Golgi. Because the reticulocyte lysate contains
significant amounts of AP-1, COPI, and AP-2 (data not shown), we
removed the endogenous coat proteins from the lysate using high speed
centrifugation and demonstrated that interaction of myrARF1 and AP-1
was dependent on the addition of exogenous AP-1. In addition, we could
not detect an interaction of [35S]ARF-(Tmd)Phe-46 and
AP-1 in solution, either in the cross-linking assay in the absence of
ISGs or by co-sedimentation of ARF1 with AP-1 during the centrifugation.
S, we observed
cross-linking of COPI to [35S]ARF-(Tmd)Phe-46, which was
dependent upon membranes. The amount of
-COPI cross-linked is at
least as great as AP-1.
-COP is present, but not enriched, in the
ISG fraction. Although Golgi contamination in the ISG fractions has
been excluded with assays for trans-Golgi network 38 (37),
sialyltransferase assays and labeling with [35S]sulfate
(38), endosomal membrane contaminants maybe present in the ISG fraction
(39), which may explain the cross-linking of
- and
-COPI.
Alternatively, the observations of Martínez-Menárguez et al. (40), showing low but significant labeling of ISGs
with COPI in the exocrine pancreas by immunoelectron microscopy,
suggest that COPI binding sites may be present on ISG membranes.
However, clathrin coats were far more abundant than the COPI coats,
suggesting that COPI-mediated transport is a minor pathway and may be a
remnant of the retrograde machinery from the Golgi complex.
,
,
, and
) have arisen from coordinated gene duplications of
common ancestral genes and predicts that
-COP is homologous to
1-adaptin and
-COP to
-adaptin. The structural similarities between the adaptors and COPI could explain the cross-linking data of
Zhao et al. (20) showing cross-linking of
[35S]ARF-(Tmd)Phe-46 to
- and
-COP on Golgi
membranes and the results presented here.
- or
-subunit of one AP-1 or COPI and the
other ARF molecule with the other large subunit.
![]()
ACKNOWLEDGEMENTS
-AP mAb, and J. Brunner for advice on the
suppressor tRNA and (Tmd)Phe, G. Schiavo, J. Tooze, and M. Lowe for
critical reading of this manuscript. We are grateful to Prof. F. T. Wieland for the ARF cDNA constructs containing the amber stop
codon mutations, polyclonal COP antibodies, and helpful discussions. We
especially thank Dr. L. Zhao for technical assistance with the
photocross-linking assays.
![]()
FOOTNOTES
To whom correspondence should be addressed. Tel.: 44-207-269- 3122; Fax: 44-207-269-3417; E-mail: tooze@icrf.icnet.uk.
![]()
ABBREVIATIONS
S, guanosine 5'-(
-thio)triphosphate;
(Tmd)Phe, L-4'-(3-trifluoromethyl-3H-diazirin-3-yl)-phenylalanine;
PAGE, polyacrylamide gel electrophoresis;
myrARF1, myristoylated
ADP-ribosylation factor 1;
GDP
S, guanosine 5'-(
-thio)diphosphate;
mAb, monoclonal antibody.
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Hirst, J.,
and Robinson, M. S.
(1998)
Biochim. Biophys. Acta
1404,
173-193
2.
Marsh, M.,
and McMahon, H. T.
(1999)
Science
285,
215-220
3.
Dell'Angelica, E. C.,
Mullins, C.,
and Bonifacino, J. S.
(1999)
J. Biol. Chem.
274,
7278-7285
4.
Hirst, J.,
Bright, N. A.,
Rous, B.,
and Robinson, M. S.
(1999)
Mol. Biol. Cell
10,
2787-2802
5.
Ahle, S.,
Mann, A.,
Eichelsbacher, U.,
and Ungewickell, E.
(1988)
EMBO J.
4,
919-929
6.
Dittié, A. S.,
Hajibagheri, N.,
and Tooze, S. A.
(1996)
J. Cell Biol.
132,
523-536
7.
Robinson, M. S.
(1987)
J. Cell Biol.
104,
887-895
8.
Kirchausen, T.,
Bonifacino, J. S.,
and Riezman, H.
(1997)
Curr. Opin. Cell Biol.
9,
488-495
9.
Le Borgne, R.,
and Hoflack, B.
(1998)
Biochim. Biophys. Acta
1404,
195-209
10.
Stamnes, M. A.,
and Rothman, J. E.
(1993)
Cell
73,
999-1005
11.
Traub, L.,
Ostrom, J. A.,
and Kornfeld, S.
(1993)
J. Cell Biol.
123,
561-573
12.
Boman, A. L.,
and Kahn, R. A.
(1995)
Trends Biochem. Sci.
20,
147-150
13.
Antonny, B.,
Beraud-Dufour, S.,
Chardin, P.,
and Chabre, M.
(1997)
Biochemistry
36,
4675-84
14.
Goldberg, J.
(1998)
Cell
95,
237-248
15.
Serafini, T.,
Orci, L.,
Amherdt, M.,
Brunner, M.,
Kahn, R. A.,
and Rothman, J. E.
(1991)
Cell
67,
239-253
16.
Orci, L.,
Palmer, D. J.,
Amherdt, M.,
and Rothman, J. E.
(1993)
Nature
364,
732-734
17.
Zhu, Y.,
Traub, L. M.,
and Kornfeld, S.
(1998)
Mol. Biol. Cell
9,
1323-1337
18.
Zhao, L.,
Helms, J. B.,
Brugger, B.,
Harter, C.,
Martoglio, B.,
Graf, R.,
Brunner, J.,
and Wieland, F. T.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
4418-4423
19.
Brunner, J.
(1989)
Methods Enzymol.
172,
628-687
20.
Zhao, L.,
Helms, B. J.,
Brunner, J.,
and Wieland, F. T.
(1999)
J. Biol. Chem.
274,
14198-14203
21.
Campbell, C.,
Squicciarini, J.,
Shia, M.,
Pilch, P. F.,
and Fine, R. E.
(1984)
Biochemistry
23,
4420-4426
22.
Smythe, E.,
Carter, L. L.,
and Schmid, S. L.
(1992)
J. Cell Biol.
119,
1163-1171
23.
Laemmli, U. K.
(1970)
Nature
227,
680-685
24.
Tanigawa, G.,
Orci, L.,
Amherdt, M.,
Ravazzola, M.,
Helms, J. B.,
and Rothman, J. E.
(1993)
J. Cell Biol.
123,
1365-1371
25.
Duronio, R. J.,
Jackson-Machelski, E.,
Heuckeroth, R. O.,
Olins, P. O.,
Devine, C. S.,
Yonemoto, W.,
Slice, L. W.,
Taylor, S. S.,
and Gordon, J. I.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
1506-1510
26.
Franco, M.,
Chardin, P.,
Chabre, M.,
and Paris, S.
(1995)
J. Biol. Chem.
270,
1337-1341
27.
Helms, J. B.,
Palmer, D. J.,
and Rothman, J. E.
(1993)
J. Cell Biol.
121,
751-760
28.
Utsumi, T.,
Kuranami, J.,
Tou, E.,
Ide, A.,
Akimaru, K.,
Hung, M. C.,
and Klostergaard, J.
(1996)
Arch. Biochem. Biophys.
326,
179-184
29.
Clairmont, K. B.,
Boll, W.,
Ericsson, M.,
and Kirchhausen, T.
(1997)
Cell. Mol. Life Sci.
53,
611-619
30.
Aniento, F.,
Gu, F.,
Parton, R. G.,
and Gruenberg, J.
(1996)
J. Cell Biol.
133,
29-41
31.
Szoka, F., Jr.,
and Papahadjopoulos, D.
(1978)
Proc. Natl. Acad. Sci. U. S. A.
75,
4194-4198
32.
Deichaite, I.,
Casson, L. P.,
Ling, H. P.,
and Resh, M. D.
(1988)
Mol. Cell. Biol.
8,
4295-4301
33.
Utsumi, T.,
Tou, E.,
Takemura, D.,
Ishisaka, R.,
Yabuki, M.,
and Iwata, H.
(1998)
Arch. Biochem. Biophys.
349,
216-224
34.
West, M. A.,
Bright, N. A.,
and Robinson, M. S.
(1997)
J. Cell Biol.
138,
1239-1254
35.
Zhu, Y.,
Drake, M. T.,
and Kornfeld, S.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
5013-5018
36.
Liang, J. O.,
and Kornfeld, S.
(1997)
J. Biol. Chem.
272,
4141-4148
37.
Dittié, A. S.,
Thomas, L.,
Thomas, G.,
and Tooze, S. A.
(1997)
EMBO J.
16,
4859-4870
38.
Tooze, S. A.,
and Huttner, W. B.
(1990)
Cell
60,
837-847
39.
Dittié, A. S.,
Klumperman, J.,
and Tooze, S. A.
(1999)
J. Cell Sci.
112,
3955-3966
40.
Martínez-Menárguez, J. A.,
Geuze, H. J.,
Slot, J. W.,
and Klumperman, J.
(1999)
Cell
98,
81-90
41.
Schledzewski, K.,
Brinkmann, H.,
and Mendel, R. R.
(1999)
J Mol. Evol.
48,
770-778
42.
Amor, J. C.,
Harrison, D. H.,
Kahn, R. A.,
and Ringe, D.
(1994)
Nature
372,
704-708
43.
Greasley, S. E.,
Jhoti, H.,
Teahan, C.,
Solari, R.,
Fensome, A.,
Thomas, G. M.,
Cockcroft, S.,
and Bax, B.
(1995)
Nat. Struct. Biol.
2,
797-806
44.
Le Borgne, R.,
Griffiths, G.,
and Hoflack, B.
(1996)
J. Biol. Chem.
271,
2162-2170
45.
Bremser, M.,
Nickel, W.,
Schweikert, M.,
Ravazzola, M.,
Amherdt, M.,
Hughes, C. A.,
Sollner, T. H.,
Rothman, J. E.,
and Wieland, F. T.
(1999)
Cell
96,
495-506
46.
Stamnes, M.,
Schiavo, G.,
Stenbeck, G.,
Sollner, T. H.,
and Rothman, J. E.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13676-13680
47.
Tooze, S. A.
(1998)
Biochim. Biophys. Acta
1404,
231-244
48.
Orci, L.,
Ravazzola, M.,
Amherdt, M.,
Madsen, O.,
Vassalli, J.-D.,
and Perrelet, A.
(1985)
Cell
42,
671-681
49.
Tooze, J.,
and Tooze, S. A.
(1986)
J. Cell Biol.
103,
839-850
50.
Klumperman, J.,
Kuliawat, R.,
Griffith, J. M.,
Geuze, H. J.,
and Arvan, P.
(1998)
J. Cell Biol.
141,
359-372
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
R. Ishizaki, H.-W. Shin, H. Mitsuhashi, and K. Nakayama Redundant Roles of BIG2 and BIG1, Guanine-Nucleotide Exchange Factors for ADP-Ribosylation Factors in Membrane Traffic between the trans-Golgi Network and Endosomes Mol. Biol. Cell, June 1, 2008; 19(6): 2650 - 2660. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Lee, B. Doray, J. Govero, and S. Kornfeld Binding of cargo sorting signals to AP-1 enhances its association with ADP ribosylation factor 1-GTP J. Cell Biol., February 6, 2008; 180(3): 467 - 472. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Haberman, I. Ziv, Y. Gorzalczany, K. Hirschberg, L. Mittleman, M. Fukuda, and R. Sagi-Eisenberg Synaptotagmin (Syt) IX is an essential determinant for protein sorting to secretory granules in mast cells Blood, April 15, 2007; 109(8): 3385 - 3392. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Fernandez and G. S. Payne Laa1p, a Conserved AP-1 Accessory Protein Important for AP-1 Localization in Yeast Mol. Biol. Cell, July 1, 2006; 17(7): 3304 - 3317. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ahras, G. P. Otto, and S. A. Tooze Synaptotagmin IV is necessary for the maturation of secretory granules in PC12 cells J. Cell Biol., April 24, 2006; 173(2): 241 - 251. < |